Research Brief: An increase in the state's HPV vaccination rate would reduce the number of preventable cancers and the financial burden that treatment for these cases would create, the study found.
“We can no longer look at this disease as one in which we should always be measuring survival in months,” said UCLA’s Dr. Edward Garon, the lead author.
The findings will both help identify women who are at highest risk of developing ovarian cancer and pave the way for identifying new therapies that can target these specific genes.
“As our treatments become more technical and expensive, it is our responsibility to prove that these treatments lead to benefits that warrant the increased cost,” said UCLA’s Dr. Ann Raldow, the study's first author.
The findings answer questions that have been sought ever since 2005, when two Australian scientists won a Nobel Prize for their discovery of H. pylori and its role in gastric conditions.
The study could have implications for addressing value in the field of radiation medicine, a traditionally male-dominated specialty, according to UCLA's Dr. Luca Valle.
“We now have a rational and logical way to develop immunotherapies going forward and a clinical development process for doing it,” said UCLA's Dr. Timothy Cloughesy.
A technique they developed coaxes pluripotent stem cells — which can can be grown indefinitely in the lab — into becoming mature T cells capable of killing tumor cells.
In this Q&A, Paul Boutros explains how scientists take cancer data, including DNA sequencing combined with clinical records, to design personal treatments.